Effects of 3-Month Astaxanthin Supplementation on Cardiac Function in Heart Failure Patients with Left Ventricular Systolic Dysfunction-A Pilot Study
Open Access
- 26 June 2020
- Vol. 12 (6), 1896
- https://doi.org/10.3390/nu12061896
Abstract
Astaxanthin has strong antioxidant properties. We conducted a prospective pilot study on heart failure (HF) patients with left ventricular (LV) systolic dysfunction to investigate improvements in cardiac function and exercise tolerance in relation to suppression of oxidative stress by 3-month astaxanthin supplementation. Oxidative stress markers—serum Diacron reactive oxygen metabolite (dROM), biological antioxidant potential (BAP), and urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) concentrations, LV ejection fraction (LVEF), and 6-min walk distance (6MWD) were assessed before and after 3-month astaxanthin supplementation. Finally, the data of 16 HF patients were analyzed. Following 3-month astaxanthin supplementation, dROM level decreased from 385.6 ± 82.6 U.CARR to 346.5 ± 56.9 U.CARR (p = 0.041) despite no changes in BAP and urinary 8-OHdG levels. LVEF increased from 34.1 ± 8.6% to 38.0 ± 10.0% (p = 0.031) and 6MWD increased from 393.4 ± 95.9 m to 432.8 ± 93.3 m (p = 0.023). Significant relationships were observed between percent changes in dROM level and those in LVEF. In this study, following 3-month astaxanthin supplementation, suppressed oxidative stress and improved cardiac contractility and exercise tolerance were observed in HF patients with LV systolic dysfunction. Correlation between suppression of oxidative stress and improvement of cardiac contractility suggests that suppression of oxidative stress by astaxanthin supplementation had therapeutic potential to improve cardiac functioning.This publication has 25 references indexed in Scilit:
- Effect of Astaxanthin on Cycling Time Trial PerformanceInternational Journal of Sports Medicine, 2011
- Effects of Astaxanthin on Oxidative Stress in Overweight and Obese AdultsPhytotherapy Research, 2011
- Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humansNutrition & Metabolism, 2010
- Bioavailability of Astaxanthin inHaematococcusAlgal Extract: The Effects of Timing of Diet and Smoking HabitsBioscience, Biotechnology, and Biochemistry, 2009
- Revised Equations for Estimated GFR From Serum Creatinine in JapanAmerican Journal of Kidney Diseases, 2009
- Astaxanthin: A Novel Potential Treatment for Oxidative Stress and Inflammation in Cardiovascular DiseaseThe American Journal of Cardiology, 2008
- Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery NarrowingsThe American Journal of Cardiology, 2008
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Astaxanthin Limits Exercise-Induced Skeletal and Cardiac Muscle Damage in MiceAntioxidants and Redox Signaling, 2003
- Absorption, transport and metabolism of carotenoids in humansPure and Applied Chemistry, 1994